Core Viewpoint - A class action has been filed against Vistagen Therapeutics, Inc. for allegedly misleading investors regarding the viability of its Phase 3 trial study of fasedienol, leading to significant financial losses for shareholders [1][2]. Group 1: Allegations and Trial Results - Robbins LLP is investigating allegations that Vistagen Therapeutics misled investors about the success of its Phase 3 PALISADE-3 trial of fasedienol, which was intended for treating social anxiety disorder [2]. - On December 17, 2025, Vistagen announced that the PALISADE-3 trial did not show a statistically significant improvement on its primary endpoint, leading to a dramatic stock price decline from $4.36 to $0.86, a drop of over 80% [3]. Group 2: Class Action Participation - Shareholders who purchased Vistagen's common stock between April 1, 2024, and December 16, 2025, may be eligible to participate in the class action and can contact Robbins LLP to serve as lead plaintiff [1][4]. - Participation in the class action is not mandatory for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 3: Company Background - Vistagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neuropsychiatric and neurological disorders [1].

2025年，深圳市福田区经济总量预计突破6000亿元、增速全市领先！近日，福田区八届五次党代会暨区 委经济工作会议召开，会上透露了去年福田经济发展的关键数据。 经济总量预计突破6000亿元的背后，动力何来？福田区持续推进"CBD+科创区"战略转型，"硬科技+硬 金融"跑出加速度，为福田高质量发展提供了强有力的支撑。 高质量发展的成果，来自前瞻布局与持续深耕。"十四五"期间，福田区深入实施全国首个区县级《现代 化产业体系中长期发展规划》，瞄准"CBD+科创区"发展战略，推动产业结构实现战略性调整。五年 来，福田新增新能源、智能终端、软件信息服务业3个千亿级"新质"产业集群，生物医药、半导体2个百 亿级"新质"产业集群产值实现倍增，专精特新"小巨人"企业较"十三五"翻五番。战略性新兴产业增加值 突破千亿大关，工业对GDP增量的贡献率从2.9%增至13.2%。 产业能级跨越新台阶，规上工业产值跨越3000亿元台阶，人工智能产业集群产值倍增。创新主体实现新 突破，新注册科技服务业与软件信息服务业企业超1.3万家、创近10年新高，新落地机器人企业数量翻 番，新增独角兽企业3家。创新生态迸发新活力，概念验证中心和中小试基 ...

Core Viewpoint - DBV Technologies has successfully raised €166.7 million through the full exercise of ABSA and BS Warrants, which will support the launch of the VIASKIN® Peanut patch for children aged 4 to 7 years in the U.S., pending approval [1][11]. Financing Details - The financing involved the issuance of 34,090,004 ABSA Warrants and 71,005,656 BS Warrants, leading to the issuance of 59,657,507 new ordinary shares and up to 124,259,898 pre-funded warrants [1][5]. - The exercise price for the ABSA Warrants was €1.5939, while the BS Warrants had an exercise price of €1.5764 [1][6]. Use of Proceeds - The gross proceeds from the exercise will be utilized for working capital, general corporate purposes, and to finance the preparation and submission of a potential Biologics License Application (BLA) for the VIASKIN® Peanut patch [10][11]. - The total financing, including potential exercises of outstanding warrants, is estimated to reach approximately €284.5 million [10]. Shareholder Impact - The issuance of new shares will dilute existing shareholders' equity, with ownership interest for a shareholder holding 1.00% of the Company's share capital decreasing to 0.78% on a non-diluted basis after the issuance [15]. - The shareholding structure will change post-issuance, with Baker Brothers Investments retaining 8.64% and Janus Henderson acquiring 7.54% of the diluted share capital [17]. Company Overview - DBV Technologies is a late-stage biopharmaceutical company focused on developing treatments for food allergies using its proprietary VIASKIN® patch technology [19]. - The company is headquartered in Châtillon, France, with operations in North America [20].

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) common stock between April 1, 2024 and December 16, 2025, both dates inclusive (the "Class Period†). Vistagen is a clinical-stage biopharmaceutical company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegati. ...

As filed with the U.S. Securities and Exchange Commission on January 16, 2026 Registration No. 333-292331 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ____________________________ ESTRELLA IMMUNOPHARMA, INC. (Exact Name of Registrants as Specified in its Charter) ____________________________ | Delaware | 6770 | 86-1314502 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard I ...

Biopharmaceutical company Agomab Therapeutics filed for an initial public offering in the United States on Friday. ...

Designation further supports (Z)-Endoxifen program into rare pediatric neuromuscular disease along with previously received Rare Pediatric Disease Designation SEATTLE, Jan. 16, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced that the U.S. Food and Drug Administration ("FDA") Office of Orphan Products Development ("OOPD") ha ...

Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PTSOUTH SAN FRANCISCO, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced that it will host a conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET (5:00 am PT) to report the results from cohort 4 of the randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with ...

As filed with the Securities and Exchange Commission on January 16, 2026 Registration No. 333-291852 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment No. 3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Edison Oncology Holding Corp. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Nevada 2836 83-1614120 (I.R.S. Employer Identification Number) 3475 Edison Way, S ...